Icariin alleviates atherosclerosis by regulating the miR-205-5p/ERBB4/AKT signaling pathway

Peng Huang1, Fengjun Wang2, Yibing Zhang3

  • 1Department of Experimental Pharmacology and Toxicology, School of Pharmacy, Jilin University, Changchun, China.

Insights

Icariin (ICA) effectively treats atherosclerosis (AS) by reducing lipid accumulation and plaque formation. It also inhibits vascular smooth muscle cell proliferation and migration, potentially via miR-205-5p.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Pharmacology

Background:

  • Atherosclerosis (AS) poses a significant global health risk.
  • Understanding therapeutic mechanisms for AS is crucial.

Purpose of the Study:

  • To investigate the therapeutic effects of icariin (ICA) on atherosclerosis.
  • To elucidate the underlying molecular mechanisms of ICA in AS treatment.

Main Methods:

  • Atherosclerosis was modeled in ApoE-/- mice and human aortic vascular smooth muscle cells (HAVSMCs).
  • Icariin treatment effects were assessed using lipid accumulation, plaque formation, cell viability, apoptosis, and migration assays.
  • MicroRNA (miRNA) profiling and in silico analyses identified potential signaling pathways, including miR-205-5p.

Main Results:

  • Icariin reduced blood lipid accumulation and plaque formation in AS mice.
  • Icariin promoted apoptosis and inhibited migration in ox-LDL-induced HAVSMCs.
  • The inhibitory effects of ICA on cell proliferation and migration were reversed by silencing miR-205-5p.

Conclusions:

  • Icariin alleviates atherosclerosis by inhibiting proliferation and migration of vascular smooth muscle cells.
  • The therapeutic action of icariin may be mediated by the upregulation of miR-205-5p.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
32
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K